FDA to review Grail's Galleri cancer test for approval after large randomized trial failed primary endpoint on August 10, 2026 Advisory Committees clinical utility clinical validity Galleri PATHFINDER PMA Premarket Approval primary endpoint United States Food and Drug Administration +